Health Affairs January 31, 2018
Kim McCleary, Kristin Schneeman

In January 2017, uncertainty over consequences of the 2016 election consumed the biomedical research and development (R&D) ecosystem. One year later, much uncertainty remains, although early anxiety has been calmed somewhat by steady leadership at the National Institutes of Health (NIH) and the Food and Drug Administration (FDA). To be sure, there is still ambiguity in the R&D field around many issues, such as concern about future federal funding levels, the impact of possible drug price reforms and enhanced generic competition, and attitudes toward scientific inquiry. Industry nonetheless seems to be reassured by a favorable tax bill, the lack of action thus far on drug pricing, a strong stock market, and the nomination of one of its own as secretary...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: AI (Artificial Intelligence), Big Data, Biotechnology, Cures Act, Market Research, Patient / Consumer, Precision Medicine, Value Based
Nelson Advisors NHS Market Research and Analysis for Future Health Intelligence
AI and Interoperability Trends: Black Book's AMIA Membership Survey Highlights Key Challenges and Opportunities in Healthcare IT
Health Systems Want Deep Guidance from Their Vendors When it Comes to AI, KLAS Finds
Virtual Care Platforms Experience Unprecedented Growth, Ushering in the Next Era of Hybrid Healthcare, Reports Black Book Research
19 top tech platforms for value-based care, population health

Share This Article